Your browser is no longer supported. Please, upgrade your browser.
Settings
ASNS Arsanis, Inc. daily Stock Chart
ASNS [NASD]
Arsanis, Inc.
Index- P/E- EPS (ttm)-3.45 Insider Own18.25% Shs Outstand14.67M Perf Week-5.23%
Market Cap23.91M Forward P/E- EPS next Y-1.49 Insider Trans- Shs Float11.70M Perf Month-9.44%
Income-45.60M PEG- EPS next Q-0.65 Inst Own79.90% Short Float1.01% Perf Quarter-91.01%
Sales- P/S- EPS this Y-41.30% Inst Trans-3.33% Short Ratio0.63 Perf Half Y-92.58%
Book/sh2.64 P/B0.62 EPS next Y39.40% ROA-74.50% Target Price13.13 Perf Year-
Cash/sh3.41 P/C0.48 EPS next 5Y- ROE-277.70% 52W Range1.65 - 28.69 Perf YTD-87.23%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-94.32% Beta-
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low-1.21% ATR0.17
Employees40 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)35.76 Volatility9.23% 9.09%
OptionableNo Debt/Eq0.30 EPS Q/Q-60.50% Profit Margin- Rel Volume0.38 Prev Close1.69
ShortableYes LT Debt/Eq0.20 EarningsAug 09 Payout- Avg Volume186.48K Price1.63
Recom2.80 SMA20-12.69% SMA50-26.27% SMA200-86.98% Volume71,241 Change-3.55%
Aug-20-18 07:55AM  New Research: Key Drivers of Growth for Harmonic, Astec Industries, Marlin Business Services, Arsanis, SunOpta, and Rhythm Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-14-18 08:23AM  The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut Benzinga
Aug-13-18 08:00AM  Arsanis Reports Financial Results for Second Quarter 2018 GlobeNewswire -19.03%
Jul-16-18 07:26AM  Arsanis Enters Oversold Territory Zacks
Jun-28-18 01:05PM  INVESTOR ALERT: Investigation of Arsanis Announced by Holzer & Holzer Business Wire -78.01%
07:00AM  Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100 GlobeNewswire
Jun-14-18 08:00AM  Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program GlobeNewswire
Jun-05-18 07:50AM  Investor Expectations to Drive Momentum within Oxford Immunotec Global, Financial Engines, Brookfield Property Partners, Arsanis, QIWI, and Stitch Fix Discovering Underlying Factors of Influence GlobeNewswire
May-10-18 07:00AM  Arsanis Reports Business Highlights and Financial Results for First Quarter 2018 Business Wire
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-17-18 08:00AM  Arsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious Diseases Business Wire +8.45%
Apr-09-18 07:40AM  Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-04-18 08:00AM  Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies Business Wire +7.97%
Mar-20-18 08:00AM  Arsanis to Present at the Needham & Company 17th Annual Healthcare Conference Business Wire +9.37%
Mar-17-18 08:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Mar-15-18 08:10AM  Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +5.47%
Mar-14-18 08:00AM  Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies Business Wire +5.98%
Mar-09-18 07:00AM  Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 Business Wire
Mar-05-18 08:00AM  Arsanis to Present at the 38th Annual Cowen and Company Health Care Conference Business Wire
Dec-29-17 04:25PM  What You Must Know About Arsanis Incs (NASDAQ:ASNS) ROE Simply Wall St.
Nov-20-17 04:10PM  Arsanis Announces Closing of Initial Public Offering Business Wire
Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.